May 31st, 2018

Also our second patent is now granted/issued in China.

April 20th, 2018

The intermediate results for Clinical Trial 3 are promising.

More than 90% of the women tested so far got leak tight, when using our device. This is a remarkable feat, considering that volunteers belong to the most diffucult group of stress incontinent women, namely those who are signed up for and ready to risk sling surgery. Further, and just as remarkable : Our one-size-fits-all approach seems feasible. We will strengthen the statistics and include more test users in the coming two months.

Please note, that all test persons in Clinical Trial 3 are recruited among the patients already in treatment at the Clinic for Urogynecology, Copenhagen University Hospital. We cannot sign up any via this website, sorry. 

November 9th, 2017

All approvals are in place, all devices are manufactured, and we have now started Clinical Trial 3 at Copenhagen University Hospital. This study will focus on women who are signed up for sling surgery, so that we test together with those who have the worst cases.

August 23rd, 2017

We have decided to do a third clinical trial, in which we will include a larger group of users than in the previous tests at Copenhagen University Hospital. This new group will evaluate our one-size-fits-all device. All moulding tools are made, and testing is scheduled to start in November. 

July 11th, 2017

Copenhagen University Hospital has finialized the clinical trials, which confirmed our expectations: The device is efficient, safe and the comfort is good. No complications were observed. A very positive observation is that a one-size-fits-all seems possible. We have tested four different sizes of our device, and can now conclude, which dimension will fit all.

This means, that our public fund project with Innovationsfonden, announced May 12th 2016, is now finished. All milestones are succesfully met. Our second public project support, from Markedsmodningsfonden, announced October 28th, continues in the year to come and supports our work on obtaining the CE-mark. 

March 10th, 2017

We have today started recruiting volunteers for a series of clinical trials at the Copenhagen University Hospital in Denmark. If you suffer from stress incontinence, live in Copenhagen, and are interested in participation, then please visit www.forsø for more information and contact details.

November 1st, 2016

It is a pleasure to welcome Kristian Uggerhøj as the MagCath's new CEO. Kristian Uggerhøj has a long career in sales and marketing of medical devices.

Niels Erikstrup continues as our CTO, responsible for all technical matters, which includes product development, manufacturing and regulatory affairs.

October 28th, 2016

We are pleased to announce that Markedsmodningsfonden will support DKK 2,1 million to MagCath ApS. The funds are dedicated a DKK 5,5 million project, covering clinical trials and the CE-marking of our device.


September 21st, 2016

Today, the European Patent Office officially granted us a patent for our device.


July 8th, 2016

Our road to the CE-mark will be paved by Greendale Medical Engineering ApS, with whom we today signed a contract for the assistance in all regultory, matters until the CE-mark is issued.

May 12th, 2016

It is now official, that MagCath ApS receives support from Innoboost, sponsored by Innovationsfonden. Innoboost will provide a total of DKK 474.760 to our product development.

December 15th, 2015

MagCath ApS receives a substantial investment from PreSEED Innovation and SEED Capital. This investment brings us a huge step forward, as it both funds our product development and allows us to form a strong board.